Previous 10 | Next 10 |
Nevro Corp. (NVRO) Q4 2018 Earnings Conference Call February 21, 2019 4:30 PM ET Company Participants Juliet Cunningham – Vice President of Investor Relations Rami Elghandour – President and Chief Executive Officer Andrew Galligan – Chief Financial Officer ...
Nevro (NYSE: NVRO ): Q4 GAAP EPS of -$0.32 misses by $0.11 . More news on: Nevro, Earnings news and commentary, Healthcare stocks news, Read more ...
REDWOOD CITY, Calif. , Feb. 21, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the fourth quarter and full year ended Decembe...
AAOI , ACIA , ADSW , AL , AMH , ANIK , APPN , ATUS , BEAT , BIDU , BJRI , BMRN , BOOM , BYD , CATM , CBPX , CENX , CHSP , COLD , CUBE , CWST , CZR , DBX , DXCM , EBS , ECOL , ED , ENV , EVRG , EXAS , FIX , FLR , FSLR , GMED , HALO , HCC , HPE , HTGC , ...
Nevro (NYSE: NVRO ) has filed a lawsuit for patent infringement against Stimwave Technologies. More news on: Nevro, Healthcare stocks news, Read more ...
REDWOOD CITY, Calif. , Feb. 15, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent infringement against Stimwave Tech...
REDWOOD CITY, Calif. , Feb. 7, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the company will release its financial results for the fourth q...
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CoreLogic, Inc. (NYSE:CLGX), Nasdaq, Inc. (NASDAQ:NDAQ), Nevro Corp. (...
Shares of medical device firm Nevro (NVRO) have lost 46% of their value since my February 2017 article stated that this medtech runner had further upside. The stock is in the red by 39% since my January 2018 article stated a rebound was likely in the year ahead. With the chart showing si...
LOS ANGELES, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Nevro Corp. (NYSE: NVRO ) (“Nevro” or “the Company”) and whether the Company ...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...